Pds Biotechnology Corp (PDSB) — SEC Filings
Pds Biotechnology Corp (PDSB) — 50 SEC filings. Latest: EFFECT (Apr 29, 2026). Includes 41 8-K, 2 10-K, 2 10-Q.
View Pds Biotechnology Corp on SEC EDGAR
Overview
Pds Biotechnology Corp (PDSB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 29, 2026: PDS Biotechnology Corp. filed an EFFECT form, indicating the effectiveness of a registration statement. The effectiveness date was April 28, 2026, with the filing accepted on April 29, 2026. The company is located at 303A College Road East, Princeton, NJ 08540.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bearish, 48 neutral, 1 mixed. The dominant filing sentiment for Pds Biotechnology Corp is neutral.
Filing Type Overview
Pds Biotechnology Corp (PDSB) has filed 1 EFFECT, 41 8-K, 2 10-K, 2 10-Q, 2 DEF 14A, 1 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of PDSB's 44 recent filings, 2 were flagged as high-risk, 14 as medium-risk, and 28 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Gandhapudi, et al.
- Rumfield et al
- Dr. Alok Sharma
- Frank Bedu-Addo, Ph.D.
- Otis Brawley, M.D.
Industry Context
PDS Biotechnology operates in the highly competitive and rapidly evolving clinical-stage immunotherapy sector. The industry is characterized by significant investment in novel drug discovery and development, particularly in oncology and infectious diseases. Key trends include the advancement of T cell-based therapies, combination treatments, and the pursuit of expedited regulatory pathways for promising candidates.
Top Tags
8-K (17) · corporate-filing (10) · financials (9) · sec-filing (7) · filing (5) · disclosure (4) · material-agreement (4) · regulatory-filing (4) · biotechnology (4) · corporate-update (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Effectiveness Date | 2026-04-28 | The date the registration statement became effective. |
| Filing Acceptance Date | 2026-04-29 | The date the SEC accepted the filing. |
| Aggregate market value of common equity held by non-affiliates | $60,145,221 | as of June 30, 2025, indicating current market valuation |
| Shares of common stock outstanding | 55,815,653 | as of March 23, 2026, relevant for per-share calculations and potential dilution |
| Fiscal year ended | 2025 | the period covered by this 10-K filing |
| Filing date | 2026-03-30 | date the 10-K was submitted to the SEC |
| Dendritic cell uptake of Versamune | 80% | in studies, indicating high efficiency of the platform |
| Time for Versamune uptake | 4 hours | following a single subcutaneous injection in studies |
| SEC File Number | 001-37568 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 26-4231384 | Company's tax identification number. |
| I.R.S. Employer Identification No. | 26-4231384 | Company's tax identification number. |
| Net Loss | $17.9M | for the six months ended June 30, 2025, an improvement from $18.9M in 2024 |
| Cash and Cash Equivalents | $31.9M | as of June 30, 2025, down 23.6% from $41.7M at Dec 31, 2024 |
| Research and Development Expenses | $10.0M | for the six months ended June 30, 2025, a 10.5% decrease from $11.2M in 2024 |
| General and Administrative Expenses | $6.7M | for the six months ended June 30, 2025, an 11.4% decrease from $7.6M in 2024 |
Frequently Asked Questions
What are the latest SEC filings for Pds Biotechnology Corp (PDSB)?
Pds Biotechnology Corp has 50 recent SEC filings from Jan 2024 to Apr 2026, including 41 8-K, 2 10-K, 2 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PDSB filings?
Across 50 filings, the sentiment breakdown is: 1 bearish, 48 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Pds Biotechnology Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Pds Biotechnology Corp (PDSB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Pds Biotechnology Corp?
Key financial highlights from Pds Biotechnology Corp's most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PDSB?
The investment thesis for PDSB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Pds Biotechnology Corp?
Key executives identified across Pds Biotechnology Corp's filings include Gandhapudi, et al., Rumfield et al, Dr. Alok Sharma, Frank Bedu-Addo, Ph.D., Otis Brawley, M.D..
What are the main risk factors for Pds Biotechnology Corp stock?
Of PDSB's 44 assessed filings, 2 were flagged high-risk, 14 medium-risk, and 28 low-risk.
What are recent predictions and forward guidance from Pds Biotechnology Corp?
Forward guidance and predictions for Pds Biotechnology Corp are extracted from SEC filings as they are enriched.